Patients undergoing cataract surgery at Rush Eye Associates have access to a breakthrough “trifocal” lens implant called the AcrySof® IQ PanOptix® Trifocal Intraocular Lens that received approval by the Food & Drug Administration in 2019. During investigational clinical trials, PanOptix patients were able to enjoy uninterrupted vision at near, intermediate, and distance. The results showed high patient satisfaction with more than 95% of PanOptix patients saying they would choose the same lens again.
The PanOptix lens is the first FDA-approved trifocal lens implant capable of delivering a unique combination of near, intermediate and distance vision to patients while significantly reducing the need for glasses after cataract surgery. This trifocal lens implant is designed for patients with active lifestyles who require good vision at all ranges. This would include everything from viewing books and mobile devices up close, viewing computer screens at intermediate distance, and far-off distance vision when driving. As with any intraocular lens implant, glares in the vision are possible with the PanOptix lens.
Medicare allows patients to upgrade their vision using advanced lens implant technology like the PanOptix lens. The standard intraocular lens implant is covered by medical insurance (including Medicare) but assures that you will be dependent upon glasses of some kind, including reading glasses and/or bifocals. The PanOptix lens technology is not covered by insurance. Patients are responsible for the out-of-pocket costs associated with the upgraded premium lens implant technology. See what financing options are available.